FUTURMASTER
29.11.2023 11:09:35 CET | Business Wire | Press release
FuturMaster, a leader in Supply Chain Planning solutions, today unveils its groundbreaking innovation, ‘Forecast at Scale’. Combining Machine Learning with an unprecedented capacity for processing massive datasets, ‘Forecast at Scale’ enables companies to reduce volatility by leveraging demand closer to consumers. It also considers external variables impacting demand, such as weather, events, and social trends.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128840505/en/
FuturMaster Launches 'Forecast at Scale': Introducing A New Era in Demand Planning (Photo: FuturMaster)
'Forecast at Scale' technology marks a transformative shift in utilizing data closer to consumers, often underutilized in current practices. It enables businesses to harness this data as a strategic asset, significantly enhancing ROI and providing a competitive edge in data-driven decision-making.
Gilles Lefebvre, Chief Product and R&D Officer at FuturMaster, comments: "We're thrilled to introduce 'Forecast at Scale' by FuturMaster, an innovation that redefines demand planning and aligns with our vision of helping companies ‘unleash’ the complexities of their supply chains and turn them into competitive advantages. Amidst today's volatile and uncertain business landscape, 'Forecast at Scale' empowers businesses to thrive."
Key Features of ‘Forecast at Scale’:
- Enhanced Big Data Processing: Combines distributed storage and massively parallel processing to handle vast data volumes efficiently.
- Dynamic Forecast Model Selection System: This system categorizes products and locations based on specific sales patterns, such as seasonal, stationary, or discrete. It then selects a tailored pool of forecast models for each category. Utilizing artificial intelligence, the system automatically determines and applies the most suitable forecast model for each product and location, ensuring optimal accuracy and efficiency in forecasting.
- AI-Driven External Variable Integration: Employs artificial intelligence to autonomously assess and incorporate relevant external variables into the analysis for each product and location based on sales pattern. Transforms relevant raw data into actionable insights, providing a comprehensive view of each product and location's performance and enhancing its forecast accuracy.
- Real-Time OLAP and Adjustment Capabilities: Enables instantaneous analysis and on-the-fly forecast adjustments, even with large datasets, facilitating more agile and informed business strategies.
FuturMaster's Bloom Demand Planning, now enhanced with ‘Forecast at Scale,’ is available to both new and existing clients, marking a new milestone in FuturMaster's commitment to driving innovation in supply chain planning.
To find out more, watch FuturMaster’s live session by clicking here or visit www.futurmaster.com.
About FuturMaster:
FuturMaster is a leading software vendor specializing in Supply Chain Planning and Trade Promotion Management & Optimization (TPx) solutions. Recognized as part of Gartner's Magic Quadrant, FuturMaster is renowned for its innovative approach in helping businesses navigate the complexities of supply chain planning. Its Bloom platform aids businesses in ‘unleashing’ supply chain complexities to drive growth, agility, resilience, and performance. For more information, visit www.futurmaster.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231128840505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
